Ειδήσεις: BIOPHARMACEUTICAL | PXAI

Version	Description	Date
8.42	[ADDED SOURCE REGISTRY LIST VIEW]	04/03/2026 16:19
8.41	[LOCALIZED INDEX.PHP MENU AND MODALS TO US ENGLISH]	04/03/2026 16:11
8.40	[TRANSLATED FRONTEND TO US ENGLISH]	04/03/2026 16:10
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:50
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:46
8.40	[REVERTED TO STANDARD TABLE LAYOUT (US ENGLISH)]	04/03/2026 15:40
8.39	[FIXED DB CONNECTION SCOPE IN SOURCES LOGIC]	04/03/2026 15:38
8.38	[TRANSLATED SOURCES VIEW TO US ENGLISH]	04/03/2026 15:01
8.37	[FULL FRONTEND TRANSLATION (MENU, FEED, COMMENTS, TTS) TO US ENGLISH.]	04/03/2026 14:58
8.67	[MANUAL OVERRIDE OF GREEK MENU ITEMS]	04/03/2026 13:36
8.66	[NGINX OPTIMIZED MENU FIX]	04/03/2026 13:33
8.65	[FIXED GREEK MENU ITEMS]	04/03/2026 13:32
8.60	[MENU & UI LOCALIZATION TO US ENGLISH]	04/03/2026 13:30
8.50	[FULL TRANSLATION TO US ENGLISH]	04/03/2026 13:27
9.75	[INJECTED EVENT FUSION_SUMMARY INTO FEED LOOPS TO DISPLAY AI TAGS CORRECTLY]	26/02/2026 14:44

31/03 09:31 defenseworld.net

PTC Therapeutics (NASDAQ:PTCT) Receives “Hold” Rating from Jefferies Financial Group

PTC Therapeutics Jefferies Hold rating target price biopharmaceutical stock analysis

30/03 11:46 defenseworld.net

Royalty Pharma PLC $RPRX Shares Sold by Cooper Investors PTY Ltd.

Royalty Pharma Cooper Investors 13F filing share sale biopharmaceutical investment portfolio

30/03 10:15 defenseworld.net

Assenagon Asset Management S.A. Has $4.59 Million Holdings in Ultragenyx Pharmaceutical Inc. $RARE

Assenagon Asset Management Ultragenyx Q4 holdings Assetmark Inc.biopharmaceutical SEC filing

30/03 08:10 defenseworld.net

Equities Analysts Issue Forecasts for Insmed Q2 Earnings

Insmed HC Wainwright Q2 2026 EPS biopharmaceutical analyst forecast Buy rating

29/03 10:22 defenseworld.net

Assenagon Asset Management S.A. Invests $5.34 Million in Xenon Pharmaceuticals Inc. $XENE

Assenagon Asset Management Xenon Pharmaceuticals 13F filing hedge fund investment Wellington Management share acquisition

27/03 09:38 defenseworld.net

Maze Therapeutics Shares Phase II HORIZON Data: MZE829 Cuts Proteinuria in APOL1 Kidney Disease

Maze Therapeutics MZE829 APOL1 kidney disease Phase II proteinuria HORIZON study

27/03 07:42 defenseworld.net

What is HC Wainwright’s Estimate for ACHV Q1 Earnings?

HC Wainwright Achieve Life Sciences Q1 earnings EPS estimate Buy rating target price

26/03 11:04 defenseworld.net

Incyte (NASDAQ:INCY) Receives “Buy” Rating from HC Wainwright

Incyte HC Wainwright buy rating price target Goldman Sachs biopharmaceutical

26/03 10:27 defenseworld.net

Diversified Trust Co. Has $1.40 Million Position in Incyte Corporation $INCY

Diversified Trust Co.Incyte Corporation $1.40 million Q4 stake reduction biopharmaceutical investment SEC filing

26/03 10:27 defenseworld.net

Diversified Trust Co. Has $1.40 Million Position in Incyte Corporation $INCY

Diversified Trust Co.Incyte Corporation $1.40 million Q4 stake reduction biopharmaceutical investment SEC filing

Loading...